Abstract
We assessed the relationships between chronic arsenic (As) exposure, human papilloma virus (HPV) contact and non-melanoma skin cancer (NMSC) by means of a dermatology clinic-based case–control study (42 cases and 48 controls) in Region Lagunera, Mexico, where chronic As poisoning is endemic. Exposure was determined through detailed history of residence in the As-contaminated area and measurement of As levels in drinking water and urine. We used a consensus epitope from the central region of L1 protein of the HPV family to determine antibodies against HPV. A history of As exposure and HPV seropositivity were associated with increased NMSC risks. A history of exposure to high levels of As increased the risk for NMSC (OR=4.53; P=0.11) in the group of seronegative HPV patients. A positive response to HPV significantly increased the OR for NMSC to 9.04 (P=0.01) when history showed exposure to low levels of As. Interestingly, the OR was significantly increased to 16.5 (P=0.001) when both exposure to high levels of As and HPV seropositivity were present. In addition, the presence of NMSC increased the OR (5.45; P=0.03) for a positive response to HPV when history showed exposure to low levels of As, but the OR was increased to 8.0 (P=0.005) in the cases with high exposure levels. Thus, HPV infection could constitute an additional risk factor for NMSC development in humans chronically exposed to As. However, further studies with additional populations are needed to determine the interaction between HPV and As exposure in NMSC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bidlingmeyer BA, Cohen SA, Taruin TL (1984) Rapid analysis of amino acids using precolumn derivatization. J Chromatogr 336:93–104
Bowes Bavinck JN, Gissmann L, Claas FHJ, Van Der Woude FJ, Persijn GG, Ter Schegget J, Vermeer BJ, Jochmus I, Müller M, Steger G, Gebert S, Pfister H (1993) Relation between skin cancer, humoral responses to human papillomaviruses, and HLA Class II molecules in renal transplant recipients. J Immunol 151:1579–1586
Burns LA, Sikorski EE, Saady J, Munson AE (1991) Evidence for arsenic as the immunosuppresive component of gallium arsenide. Toxicol Appl Pharmacol 110:157–169
Calderón-Aranda ES, Olamendi TP, Possani LD (1995) The use of synthetic peptides can be a misleading approach to generate vaccines against scorpion toxins. Vaccine 13:1198–1206
Calderón-Aranda ES, Gurrola G, York E, Selisko B, Stewart JM, Possani LD (1999) Mapping of an epitope recognized by a neutralizing monoclonal antibody specific to toxin Cn2 from the scorpion Centruroides noxius, using discontinuous synthetic peptides. Eur J Biochem 264:746–755
De Villiers EM (1998) Human papillomavirus infections in skin cancers. Biomed Pharmacother 52:26–33
De Villiers EM, Lavergne D, McLaren K, Benton EC (1997) Prevailing papillomavirus types in non-melanoma carcinomas of the skin in renal allograft recipients. Int J Cancer 73:356–361
Del Razo LM, Arellano MA, Cebrian ME (1990) The oxidation states of arsenic in well-water from a chronic arsenicism area of northern Mexico. Environ Pollut 64:143–153
Del Razo LM, Garcia-Vargas GG, Vargas H, Albores A, Gonsebatt ME, Montero R, Ostrosky-Wegman P, Kelsh M, Cebrian ME (1997) Altered profile of urinary arsenic metabolites in adults with chronic arsenicism: a pilot study. Arch Toxicol 71:211–217
Dillner J, Dillner L, Utter G, Eklund C, Rotola A, Costa S, DiLuca D (1990) Mapping of linear epitopes of human papillomavirus type 16: the L1 and L2 open reading frames. Int J Cancer 45:529–535
Forslund O, Nordin P, Andersson K, Stenquist B, Hansson B (1997) DNA analysis indicates patient-specific human papillomavirus type 16 strains in Bowen’s disease on fingers and in archival samples from genital dysplasia. Br J Dermatol 136:678–682
Gerdsen R, Stockfleth E, Uerlich M, Fartasch M, Steen KH, Bieber T (2000) Papular palmoplantar hyperkeratosis following chronic medical exposure to arsenic: human papillomavirus as a co-factor in the pathogenesis of arsenical keratosis? Acta Derm Venereol 80:292–293
Grimmel M, De Villiers EM, Neumann C, Pawlita M, zur Hausen H (1988) Characterization of a new human papillomavirus (HPV 41) from disseminated warts and detection of its DNA in some skin carcinomas. Int J Cancer 41:5–9
Harwood CA, Spink PJ, Surentheran T, Leigh IM, Hawke JL, Proby CM, Breuer J, McGregor JM (1998) Detection of human papillomaviruses DNA in PUVA-associated non-melanoma skin cancers. J Invest Dermatol 111:123–127
Hsueh YH, Cheng GS, Wu NM, Yu HS, Kuo TL, Chen CJ (1995) Multiple risk factors associated with arsenic-induced skin cancer; effects of chronic liver disease and nutritional status. Br J Cancer 71:109–114
Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT (1994) A virus-like particle enzyme-linked immunoadsorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 86:494–498
Kowalski LA, Tsang SS, Davison AJ (1996) Arsenic and chromium enhance transformation of bovine papillomavirus DNA-transfected C3H/10T1/2 cells. Cancer Lett 103:65–69
Lantz RC, Parliman G, Chen GJ, Carter DE (1994) Effect of arsenic exposure on alveolar macrophage function. I. Effect of soluble As (III) and As(V). Environ Res 67:183–195
Merrifield RB (1963) Solid phase peptide synthesis I. The synthesis of a tetrapeptide. J Am Chem Soc 85:2144–2154
NRC (National Research Council) (1999) Arsenic in drinking water. National Academy Press, Washington, D.C.
Ostrosky-Wegman P, Gonsebatt ME, Montero R, Vega L, Barba H, Espinosa J, Palao A, Cortinas C, Garcia-Vargas G, Del Razo LM, Cebrian M (1991) Lymphocyte proliferation kinetics and genotoxic findings in a pilot study on individuals chronically exposed to arsenic in Mexico. Mutat Res 250:477–482
Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2:533–543
Purdie KJ, Pennington J, Proby CM, Khalaf S, De Villiers EM, Leigh IM, Storey A (1999) The promoter of a novel human papillomavirus (HPV77) associated with skin cancer displays UV responsiveness, which is mediated through a consensus p53 binding sequence. EMBO J 18:5359–5369
Shamanin V, zur Hausen H, Lavergne D, Proby CM, Leigh IM, Neumann C, Hamm H, Goos M, Haustein UF, Jung EG, Plewing G, Wolff H, De Villiers EM (1996) Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J Natl Cancer Inst 88:802–811
Sikorski EE, McCay JA, White KL, Bradley SG, Munson AE (1989) Immunotoxicity of the semiconductor gallium arsenide in female B6C3F1 mice. Fundam Appl Toxicol 13:843–858
Strike DG, Bonnez W, Rose RC, Reichman RC (1989) Expression in Escherichia coli of seven DNA fragments comprising the complete L1 and L2 open reading frames of human papillomavirus type 6b and localization of the “common antigen” region. J Gen Virol 70:543–555
Swygart C (1997) Human papillomavirus: disease and laboratory diagnosis. Br J Biomed Sci 54:299–303
Tseng WP, Chu HM, How SW, Fong JM, Lin CS, Yeh S (1968) Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J Natl Cancer Inst 40:453–463
Willet W, Colditz G, Muellre N (1996) Strategies for minimizing cancer risk. Sci Am 275:88–95
Acknowledgements
This work was supported partially by grants from the Mexican Council for Science and Technology (Conacyt 26300-M) and JIRA 97 from Cinvestar-IPN to ESCA. We greatly appreciate the help of Aristides Gómez in the statistical analysis and the assistance of Eunice Vera and Timoteo Olamendi for chemical analysis. We thank CNA-GRCCN-Mexico for historical data of As.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rosales-Castillo, J.A., Acosta-Saavedra, L.C., Torres, R. et al. Arsenic exposure and human papillomavirus response in non-melanoma skin cancer Mexican patients: a pilot study. Int Arch Occup Environ Health 77, 418–423 (2004). https://doi.org/10.1007/s00420-004-0527-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00420-004-0527-0